FR940617-0-00059 FR940617-0-00010 21 CFR Part 529 Certain Other Dosage Form New Animal Drugs; Gentamicin Sulfate Intrauterine Solution AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Fort Dodge Laboratories. The ANADA provides for the use of a generic gentamicin solution for control of bacterial infections of the uterus (metritis) of horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin. EFFECTIVE DATE: June 17, 1994. FOR FURTHER INFORMATION CONTACT: Larry D. Rollins, Center for Veterinary Medicine (HFV&hyph;110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1612. SUPPLEMENTARY INFORMATION: Fort Dodge Laboratories, Fort Dodge, IA 50501, is the sponsor of ANADA 200&hyph;102, which provides for the use of a generic gentamicin solution (100 milligrams/milliliter (mg/mL)) for control of bacterial infections of the uterus (metritis) in horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin. ANADA 200&hyph;102 for Fort Dodge Laboratories' gentamicin sulfate solution (100 mg/mL gentamicin) is as a generic copy of Schering's Gentocin Solution (100 mg/mL gentamicin) in NADA 046&hyph;724. The ANADA is approved as of May 19, 1994, and the regulations are amended in 21 CFR 529.1044a to reflect the approval. The basis for approval is discussed in the freedom of information summary. In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and ยง514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. List of Subjects in 21 CFR Part 529 Animal drugs. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 529 is amended as follows: PART 529_CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS 1. The authority citation for 21 CFR part 529 continues to read as follows: Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). ยง529.1044a [Amended] 2. Section 529.1044a Gentamicin sulfate intrauterine solution is amended in paragraph (b) by removing ``000061 and 057561'' and adding in its place ``000061, 057561, and 000856''. Dated: June 9, 1994. Richard H. Teske, Acting Director, Center for Veterinary Medicine. [FR Doc. 94&hyph;14854 Filed 6&hyph;16&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
